Good evening :)
$
₹
Moleculin Biotech Inc

Moleculin Biotech Inc

MBRX

NASDAQ
Asset Logo

Moleculin Biotech Inc

MBRX

NASDAQ
$8.690.45% (-0.04)
$
₹
$8.690.45% (-0.04)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $8.6M the stock is ranked 5784

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

0.04
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.73
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$179.6
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 3 analysts reports

Buy
3 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+2649.14%

Earnings Growth

-157.71%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
50.65
50.65
1Y Return
36.01%
36.01%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.73
27.73
1Y Return
50.65%
50.65%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
42.33%
42.33%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.33
35.33
1Y Return
30.09%
30.09%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
20.57
20.57
1Y Return
40.33%
40.33%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 2649.14% growth, versus a trailing 3-year CAGR of -9.43%.

2026
Current$8.73Baseline
Analyst Target - 1 year
Target$240+2649.14%

All values in $

202220232024202520262027$71.89$135.93$199.96Target+2649.14%
2026
Current$8.73Baseline
Analyst Target - 1 year
Target$240+2649.14%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-25.35Baseline
Forecast for Dec 2026
High$-58.8-131.94%
Average$-65.33-157.71%
Low$-70.6-178.49%

All values in $

202120222023202420252026-225.99-299.55-255.97-164.81-25.35Low-178.49%Average-157.71%High-131.94%
2025
Current$-25.35Baseline
Forecast for Dec 2026
High$-58.8-131.94%
Average$-65.33-157.71%
Low$-70.6-178.49%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-25.3
15.5
-12.8
-7.6
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0.40000.120.0600000
Net Income-4.97-4.31-10.59-1.88-6.43-7.64-25.3915.55-12.84-7.63
Net Profit Margin-1224.13%---1493.65%-10215.87%-----
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Moleculin Biotech Inc 0.040.730
AbbVie Inc50.6550.450.58
Amgen Inc27.7321.332.75
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare MBRX with any stock or ETF
Compare MBRX with any stock or ETF
Comparing from
MBRX
ABBV
AMGN
Loading...

Frequently asked questions

  1. Moleculin Biotech Inc (MBRX) share price today is $8.69 as of November 6, 2026 at 8:35 PM IST. The stock touched a day high of $8.84 and a day low of $7.81.

  2. Moleculin Biotech Inc stock trades on NASDAQ under the ticker symbol MBRX.

  3. Moleculin Biotech Inc's market capitalization is $8.62M as of November 6, 2026 at 8:35 PM IST.

  4. Moleculin Biotech Inc's price-to-earnings (P/E) ratio is 0.04 as of November 6, 2026.

  5. Moleculin Biotech Inc's price-to-book (P/B) ratio is 0.73 as of November 6, 2026.

  6. Yes, You can buy Moleculin Biotech Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Moleculin Biotech Inc shares in three steps: 1. Search Moleculin Biotech Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Moleculin Biotech Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Moleculin Biotech Inc (MBRX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.1507 shares at the current price of $8.69.

Loading...